Off-Label Drug Bills Get Little Traction On Capitol Hill
Law360, New York (July 12, 2017, 5:23 PM EDT) -- Republican legislation to ease limits on off-label drug promotion faced significant pushback Wednesday on Capitol Hill, as Democrats, experts and independent groups questioned the wisdom of relaxed rules.
A roughly two-hour hearing at the House Energy & Commerce Committee looked at two draft bills to loosen off-label limits as well as the general pros and cons of off-label drug promotion. Notably, despite off-label promotion being a perennial hot topic among drugmakers, lawyers and regulators, there were suggestions Wednesday that the issue isn’t something that really needs attention from Congress.
“These issues that are being discussed here today, no one has ever...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!